Paradigm Healthcare

Paradigm Biopharmaceuticals is a late-stage clinical drug development company focused on repurposing existing drugs for new therapeutic applications in areas of high unmet medical need. The company's lead candidate is Zilosul, an injectable formulation of pentosan polysulfate sodium (iPPS), which is currently in Phase 3 clinical trials for the treatment of knee osteoarthritis. Paradigm is also investigating the potential of iPPS in treating rare lysosomal storage disorders, specifically Mucopolysaccharidosis (MPS), leveraging the drug's multi-modal anti-inflammatory and tissue-protective properties. By focusing on established molecules with known safety profiles, the company aims to accelerate the development timeline and reduce the risk associated with traditional drug discovery.